TSS
TOVX icon

Two Sigma Securities’s Theriva Biologics TOVX Stock Holding History

Two Sigma Securities’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.94K Sell
19,748
-85,493
-81% -$25.3K ﹤0.01% 1598
2026
Q1 		$20.6K Buy
105,241
+62,348
+145% +$12.3K ﹤0.01% 1369
2025
Q4 		$9.03K Buy
+42,893
New +$12.7K ﹤0.01% 1301
2025
Q3 		– Sell
-17,818
Closed -$7.73K – 1994
2025
Q2 		$7.73K Buy
+17,818
New +$14.5K ﹤0.01% 1325
2024
Q4 		– Sell
-10,120
Closed -$14K – 3169
2024
Q3 		$14K Buy
10,120
+7,679
+315% +$37.5K ﹤0.01% 2549
2024
Q2 		$14.4K Buy
2,441
+1,590
+187% +$13.9K ﹤0.01% 2760
2024
Q1 		$9.98K Buy
+851
New +$9.96K ﹤0.01% 2767
2023
Q4 		– Sell
-639
Closed -$8.61K – 3594
2023
Q3 		$8.61K Buy
+639
New +$9.72K ﹤0.01% 2719
2022
Q4 		– Sell
-734
Closed -$18K – 3264
2022
Q3 		$18K Buy
734
+455
+163% +$17.5K ﹤0.01% 2314
2022
Q2 		$15K Buy
279
+128
+85% +$7.33K ﹤0.01% 1994
2022
Q1 		$11K Buy
+151
New +$10.3K ﹤0.01% 2039
2020
Q3 		– Sell
-80
Closed -$10K – 1662
2020
Q2 		$10K Buy
+80
New +$7.62K ﹤0.01% 1314
2019
Q2 		– Sell
-75
Closed -$13K – 2421
2019
Q1 		$13K Buy
+75
New +$12.4K ﹤0.01% 1708
2018
Q4 		– Sell
-45
Closed -$29K – 2834
2018
Q3 		$29K Buy
45
+38
+543% +$42K ﹤0.01% 2401
2018
Q2 		$14K Buy
7
+4
+133% +$9.18K ﹤0.01% 2572
2018
Q1 		$8K Sell
3
-6
-67% -$22.8K ﹤0.01% 2617
2017
Q4 		$39K Buy
9
+5
+125% +$31.2K ﹤0.01% 1563
2017
Q3 		$30K Buy
+4
New +$23.1K ﹤0.01% 787
2017
Q1 		– Sell
-3
Closed -$23K – 1113
2016
Q4 		$23K Buy
+3
New +$30.8K 0.01% 648
2016
Q2 		– Sell
-1
Closed -$25K – 516
2016
Q1 		$25K Buy
+1
New +$15K 0.03% 231

Other funds holding TOVX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Two Sigma Securities's TOVX Position: Q2 2026 in Review

Two Sigma Securities reduced its Theriva Biologics (TOVX) stake by 81% in Q2 2026, selling an estimated $25.3K and leaving 19,748 shares worth $4.94K. The position accounts for ﹤0.01% of the portfolio, ranked #1598.

Two Sigma Securities first reported a position in TOVX in Q1 2016 and has held it in 20 quarters since. The position peaked at $39K in Q4 2017. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

  • Two Sigma Securities held 19,748 shares of Theriva Biologics worth $4.94K as of Q2 2026.
  • Two Sigma Securities sold 85,493 Theriva Biologics shares in Q2 2026, an estimated $25.3K.
  • Theriva Biologics made up ﹤0.01% of Two Sigma Securities's portfolio in Q2 2026, its #1598 holding.
  • Two Sigma Securities first reported a position in Theriva Biologics in Q1 2016 and has held it in 20 quarters since.
  • Two Sigma Securities's Theriva Biologics position peaked at $39K in Q4 2017.
  • 26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.